Sorafenib News and Research RSS Feed - Sorafenib News and Research

Sorafenib (Nexavar) is an oral multikinase inhibitor for the treatment of two common types of cancer, hepatocellular carcinoma (HCC) and advanced renal cell carcinoma (RCC).
Quality of life maintained during mRCC TKI therapy

Quality of life maintained during mRCC TKI therapy

Treatment with tyrosine kinase inhibitors does not appear to significantly impair health-related quality of life in Japanese patients with metastatic renal cell carcinoma, say researchers. [More]
Phase 3 trial: NEXAVAR tablets fail to meet primary endpoint in HER2-negative breast cancer patients

Phase 3 trial: NEXAVAR tablets fail to meet primary endpoint in HER2-negative breast cancer patients

Bayer HealthCare and Onyx Pharmaceuticals Inc., an Amgen subsidiary, today announced that an investigational Phase 3 trial of NEXAVAR (sorafenib) tablets in patients with advanced breast cancer did not meet its primary endpoint of improving progression-free survival (PFS). [More]
Can-Fite's CF102 drug gets approval in Israel for patient with hepatocellular carcinoma

Can-Fite's CF102 drug gets approval in Israel for patient with hepatocellular carcinoma

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that the Israeli Ministry of Health has approved the use of its drug CF102 for a patient with hepatocellular carcinoma, the most common form of liver cancer, under the country's Compassionate Use Program. [More]
Bayer announces Health Canada approval of Nexavar for differentiated thyroid cancer treatment

Bayer announces Health Canada approval of Nexavar for differentiated thyroid cancer treatment

Bayer Inc. is pleased to announce the Health Canada approval of Nexavar for the treatment of patients with locally advanced or metastatic, progressive, differentiated thyroid carcinoma (DTC), refractory to radioactive iodine (RAI). [More]
Drug everolimus fails to improve overall survival in advanced liver cancer patients

Drug everolimus fails to improve overall survival in advanced liver cancer patients

Despite strong preclinical data, the drug everolimus failed to improve overall survival in patients with advanced liver cancer, compared to placebo, according to a study in the July 2 issue of JAMA. [More]
Elderly mRCC patients should not be excluded from targeted therapy option

Elderly mRCC patients should not be excluded from targeted therapy option

Advanced age is not a reason to preclude patients from receiving vascular endothelial growth factor-targeted therapy for metastatic renal cell carcinoma, show study findings from a mixed-age patient population. [More]
18F-FGD-PET measures predict mRCC TKI response

18F-FGD-PET measures predict mRCC TKI response

Positron emission tomography could be used to predict the response of metastatic renal cell carcinoma to tyrosine kinase inhibitor therapy within a couple of weeks of a patient beginning treatment, research suggests. [More]
FDA approves Can-Fite's study protocol for CF102 Phase II clinical trial for advanced liver cancer

FDA approves Can-Fite's study protocol for CF102 Phase II clinical trial for advanced liver cancer

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that the U.S. FDA has agreed with the Company's study protocol for its Phase II clinical trial of CF102 for the treatment of advanced liver cancer. [More]

Multiple lines of targeted therapy extend life for mRCC patients

Overall survival of patients with metastatic renal cell carcinoma is extended the more lines of targeted therapy they receive, shows an evaluation of a large retrospective multicentre database. [More]

Adoptive T-cell therapy may help in treating liver cancer, says study

Significant new data presented today at the International Liver Congress- 2014 indicate that liver cancer (Hepatocellular Carcinoma (HCC)) may be treated by adoptive T-cell therapy. [More]
Researchers identify experimental drugs to block treatment-resistant leukemia

Researchers identify experimental drugs to block treatment-resistant leukemia

Research in mice and human cell lines has identified an experimental compound dubbed TTT-3002 as potentially one of the most potent drugs available to block genetic mutations in cancer cells blamed for some forms of treatment-resistant leukemia. [More]
Bayer and Onyx announce Phase 3 trial evaluating use of NEXAVAR for patients with HCC after local ablation

Bayer and Onyx announce Phase 3 trial evaluating use of NEXAVAR for patients with HCC after local ablation

Bayer HealthCare Pharmaceuticals Inc. and Onyx Pharmaceuticals, Inc., an Amgen subsidiary (Nasdaq: AMGN), today announced that a Phase 3 trial evaluating the investigational use of NEXAVAR® (sorafenib) tablets as an adjuvant treatment for patients with hepatocellular carcinoma (HCC), or liver cancer, who had no detectable disease after surgical resection or local ablation, did not meet its primary endpoint of improving recurrence-free survival. [More]
Combination treatments for unresectable and metastatic melanomas: an interview with Dr. Kiran Patel, Vice President & Medicines Development Leader for Oncology, GSK

Combination treatments for unresectable and metastatic melanomas: an interview with Dr. Kiran Patel, Vice President & Medicines Development Leader for Oncology, GSK

Melanoma is the most serious and deadly form of skin cancer. Unresectable melanoma is melanoma that has spread locally and cannot be removed by surgery, while metastatic melanoma is melanoma that has spread to other parts of the body. Both are advanced stages of melanoma and have had historically low survival rates. [More]
Pfizer and Merck join forces to explore therapeutic potential of anti-PD-1 therapy

Pfizer and Merck join forces to explore therapeutic potential of anti-PD-1 therapy

Pfizer Inc. announced today that it has agreed with Merck & Co., Inc., known as MSD outside the United States and Canada ("Merck"), through two Merck subsidiaries, to explore the therapeutic potential of Merck's investigational anti-PD-1 therapy, MK-3475, in combination with two Pfizer oncology assets. [More]
Researchers identify potential genes that can be targeted for new treatments for hepatocellular cancer

Researchers identify potential genes that can be targeted for new treatments for hepatocellular cancer

Patients with advanced hepatocellular (or liver) cancer have high mortality rates, with existing drugs demonstrating only a small, but significant survival advantage. By combining a zebrafish model of liver cancer with data from human tumors, researchers from the Icahn School of Medicine at Mount Sinai hope to identify potential genes of interest that can be targeted for new treatments for hepatocellular carcinoma, the most common form of liver cancer to develop from liver cells. [More]
Hopkins scientists design new mouse that mimics common form of leukemia

Hopkins scientists design new mouse that mimics common form of leukemia

Johns Hopkins Kimmel Cancer Center investigators have genetically engineered a new mouse that mimics a common form of leukemia in humans. Studying the model could lead to new understanding of the disease, they say. [More]
VG Life Sciences provides update to HCQ-sorafenib combination Phase I Study for advanced stage solid tumors

VG Life Sciences provides update to HCQ-sorafenib combination Phase I Study for advanced stage solid tumors

VG Life Sciences, a biotechnology company, announces today an update to its Physician-IND Phase I Study to test tolerability and toxicity of its patented technology in patients with advanced stage solid tumors. [More]
Novartis to present updates on broad cancer portfolio at ASH and SABCS symposiums

Novartis to present updates on broad cancer portfolio at ASH and SABCS symposiums

Novartis will present updates on its broad cancer portfolio with more than 240 abstracts at the upcoming American Society of Hematology (ASH) annual meeting and CTRC-AACR San Antonio Breast Cancer Symposium (SABCS). [More]
NEXAVAR tablets receive FDA approval for treatment of patients with thyroid cancer

NEXAVAR tablets receive FDA approval for treatment of patients with thyroid cancer

Bayer HealthCare and Onyx Pharmaceuticals, Inc., an Amgen subsidiary, today announced that the U.S. Food and Drug Administration has approved a supplemental New Drug Application for the oral multi-kinase inhibitor NEXAVAR (sorafenib) tablets for the treatment of patients with locally recurrent or metastatic, progressive, differentiated thyroid carcinoma refractory to radioactive iodine treatment. [More]
New drug combination therapy effectively kills cancer cells

New drug combination therapy effectively kills cancer cells

Results from a recent preclinical study have shown that a new drug combination therapy being developed at Virginia Commonwealth University Massey Cancer Center effectively killed colon, liver, lung, kidney, breast and brain cancer cells while having little effect on noncancerous cells. The results lay the foundation for researchers to plan a future phase 1 clinical trial to test the safety of the therapy in a small group of patients. [More]